ZA200200889B - Combination therapy using pentafluorobenzenesulfonamides. - Google Patents

Combination therapy using pentafluorobenzenesulfonamides. Download PDF

Info

Publication number
ZA200200889B
ZA200200889B ZA200200889A ZA200200889A ZA200200889B ZA 200200889 B ZA200200889 B ZA 200200889B ZA 200200889 A ZA200200889 A ZA 200200889A ZA 200200889 A ZA200200889 A ZA 200200889A ZA 200200889 B ZA200200889 B ZA 200200889B
Authority
ZA
South Africa
Prior art keywords
group
amount
och
accordance
composition
Prior art date
Application number
ZA200200889A
Other languages
English (en)
Inventor
Susan Schwendner
Pieter Timmermans
Jackie Walling
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of ZA200200889B publication Critical patent/ZA200200889B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Weting (AREA)
ZA200200889A 1999-07-29 2002-01-31 Combination therapy using pentafluorobenzenesulfonamides. ZA200200889B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14643699P 1999-07-29 1999-07-29

Publications (1)

Publication Number Publication Date
ZA200200889B true ZA200200889B (en) 2003-03-26

Family

ID=22517356

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200889A ZA200200889B (en) 1999-07-29 2002-01-31 Combination therapy using pentafluorobenzenesulfonamides.

Country Status (16)

Country Link
US (1) US6355628B1 (https=)
EP (1) EP1206256B8 (https=)
JP (1) JP2003505513A (https=)
KR (1) KR100685059B1 (https=)
CN (1) CN1181819C (https=)
AT (1) ATE294574T1 (https=)
AU (1) AU775305B2 (https=)
CA (1) CA2380078C (https=)
DE (1) DE60019937T2 (https=)
DK (1) DK1206256T3 (https=)
ES (1) ES2241639T3 (https=)
IL (2) IL147890A0 (https=)
PT (1) PT1206256E (https=)
RU (1) RU2268054C2 (https=)
WO (1) WO2001008693A2 (https=)
ZA (1) ZA200200889B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69724777T2 (de) * 1996-02-22 2004-07-15 Tularik, Inc., South San Francisco Pentafluorobenzensulfonamiden und analoge
PT939627E (pt) * 1996-07-19 2004-02-27 Tularik Inc Pentafluorobenzenossulfonamidas e analogos
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
FR2834641B1 (fr) * 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
WO2005051303A2 (en) * 2003-11-19 2005-06-09 Lixin Zhang Screening for synergistic compounds
US10238831B2 (en) 2013-09-08 2019-03-26 Qool Therapeutics, Inc. Temperature measurement and feedback for therapeutic hypothermia
CN107530187B (zh) 2015-02-23 2020-06-30 库尔诊疗公司 用于冷冻颗粒的气管内递送的系统
EP3676255B1 (en) 2017-08-29 2025-04-16 Rutgers, The State University University Of New Jersey Therapeutic indazoles
EP3684754A4 (en) * 2017-09-21 2021-06-02 Dalriada Therapeutics Inc. PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND ASSOCIATED USES

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH362688A (de) 1957-09-10 1962-06-30 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (nl) 1970-04-13 1984-07-16 Minnesota Mining & Mfg Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking.
SE447902B (sv) * 1977-10-19 1986-12-22 Johnson Matthey Co Ltd Cis-koordinationsforening av platina och komposition innehallande foreningen
DE3623184A1 (de) 1986-07-10 1988-01-14 Kali Chemie Ag Verfahren zur herstellung von n-fluorsulfonamiden
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2645537B1 (fr) 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
RU2088288C1 (ru) * 1993-07-29 1997-08-27 Московский областной научно-исследовательский клинический институт Способ лечения больных местнораспространенными формами рака
RU2098096C1 (ru) * 1993-10-11 1997-12-10 Московский научно-исследовательский онкологический институт им.П.А.Герцена Средства, подавляющие рост раковых клеток
WO1996040629A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
DE69724777T2 (de) 1996-02-22 2004-07-15 Tularik, Inc., South San Francisco Pentafluorobenzensulfonamiden und analoge
PT939627E (pt) * 1996-07-19 2004-02-27 Tularik Inc Pentafluorobenzenossulfonamidas e analogos
CZ298022B6 (cs) * 1996-10-15 2007-05-30 G. D. Searle & Co. Použití inhibitoru cyklooxygenázy-2 pro výrobu léciva pro lécení a prevenci neoplazie
JP2001505564A (ja) * 1996-11-19 2001-04-24 ジー．ディー．サール アンド カンパニー 抗血管新生剤としてのシクロオキシゲナーゼ―２阻害剤の使用方法
US5773236A (en) 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
ATE248845T1 (de) * 1998-06-25 2003-09-15 Tularik Inc Arylsulfonanilid-phosphate
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
AU2190700A (en) * 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular

Also Published As

Publication number Publication date
CA2380078C (en) 2008-05-06
EP1206256B1 (en) 2005-05-04
EP1206256B8 (en) 2005-06-29
WO2001008693A3 (en) 2001-05-25
US6355628B1 (en) 2002-03-12
KR20020050225A (ko) 2002-06-26
DK1206256T3 (da) 2005-08-15
ES2241639T3 (es) 2005-11-01
CA2380078A1 (en) 2001-02-08
CN1181819C (zh) 2004-12-29
AU6615200A (en) 2001-02-19
PT1206256E (pt) 2005-09-30
EP1206256A2 (en) 2002-05-22
AU775305B2 (en) 2004-07-29
RU2002105374A (ru) 2004-01-10
KR100685059B1 (ko) 2007-02-22
JP2003505513A (ja) 2003-02-12
CN1367690A (zh) 2002-09-04
IL147890A (en) 2007-07-04
WO2001008693A2 (en) 2001-02-08
RU2268054C2 (ru) 2006-01-20
DE60019937T2 (de) 2006-05-04
IL147890A0 (en) 2002-08-14
ATE294574T1 (de) 2005-05-15
DE60019937D1 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
EP2786756B1 (en) Combination therapy with a topoisomerase inhibitor
RU2587013C2 (ru) Комбинированная химиотерапия
CN100363004C (zh) 喹唑啉衍生物zd6474组合吉西他滨在制备药物中的用途
AU775305B2 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
JP2019526560A (ja) グルタミナーゼ阻害剤との併用療法
US6822001B2 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
ZA200305967B (en) Method of cancer therapy
RU2284818C2 (ru) Комбинированная химиотерапия
MXPA97003949A (en) Chemotherapy in combination of suramine and a vinca-alcaloide or estramust
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202421B (en) Combination therapy with an antitumor antibiotic